Regeneron price target raised to $753 from $750 at Bernstein

Bernstein analyst William Pickering raised the firm’s price target on Regeneron (REGN) to $753 from $750 and keeps an Outperform rating on the shares. The company reported a “very strong” Q2 but also announced a new round of regulatory setbacks, the analyst tells investors in a research note. The firm says an FDA inspection at an ex-Catalent site has led to a second complete response letter for odronextemab and an expected delay in pending FDA decisions on Eylea.